Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review.

ABSTRACT: Standard of care for high-risk cutaneous squamous cell carcinoma (cSCC) is surgical excision of the primary lesion with clear margins when possible, and additional resection of positive margins when feasible. Even with negative margins, certain high-risk factors warrant consideration of adjuvant therapy. However, which patients might benefit from adjuvant therapy is unclear, and supporting evidence is conflicting and limited to mostly small retrospective cohorts. Here, we review literature from the last decade regarding adjuvant radiation therapy and systemic therapy in high-risk cSCC, including recent and current trials and the role of immune checkpoint inhibitors. We demonstrate evidence gaps in adjuvant therapy for high-risk cSCC and the need for prognostic tools, such as gene expressio

SUBMITTER: Newman JG 

PROVIDER: S-EPMC8453797 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature